"It so happens that this year, the compounds that represent the kind of novel approach to medicine that we want to develop happen to be in phase I or phase II, " says Dennis Burns , the head of global business development at Hoffman-La Roche , Roche's U.S.-based drug division.
FORBES: Magazine Article